Eli Lilly (LLY) Shares Outstanding (Diluted Average) (2012 - 2026)

Eli Lilly has reported Shares Outstanding (Diluted Average) for 15 years, with the latest figure at $895.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) fell 0.52% year-over-year to $895.9 million; the trailing twelve-month figure through Mar 2026 stood at $895.9 million (down 0.52% YoY), and the FY2025 full-year result was $899.3 million, down 0.53% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $895.9 million, roughly flat from $899.3 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $906.4 million in Q1 2022, with the low at $895.9 million in Q1 2026.
• Historically, Shares Outstanding (Diluted Average) has averaged $902.6 million across 5 years, with a median of $903.3 million in 2023.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Diluted Average) slipped 0.79% — and 2024, when it rose 0.14%.
• Eli Lilly's Shares Outstanding (Diluted Average) stood at $904.6 million in 2022, then dropped by 0.15% to $903.3 million in 2023, then climbed by 0.09% to $904.1 million in 2024, then fell by 0.53% to $899.3 million in 2025, then fell by 0.38% to $895.9 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $895.9 million (Q1 2026), $899.3 million (Q4 2025), and $898.8 million (Q3 2025), per Business Quant data.